Long-acting amylin analogues for the management of obesity

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Long-acting amylin analogues for the management of obesity. / Mathiesen, David S.; Bagger, Jonatan I.; Knop, Filip K.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 29, No. 2, 2022, p. 183-190.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Mathiesen, DS, Bagger, JI & Knop, FK 2022, 'Long-acting amylin analogues for the management of obesity', Current Opinion in Endocrinology, Diabetes and Obesity, vol. 29, no. 2, pp. 183-190. https://doi.org/10.1097/MED.0000000000000716

APA

Mathiesen, D. S., Bagger, J. I., & Knop, F. K. (2022). Long-acting amylin analogues for the management of obesity. Current Opinion in Endocrinology, Diabetes and Obesity, 29(2), 183-190. https://doi.org/10.1097/MED.0000000000000716

Vancouver

Mathiesen DS, Bagger JI, Knop FK. Long-acting amylin analogues for the management of obesity. Current Opinion in Endocrinology, Diabetes and Obesity. 2022;29(2):183-190. https://doi.org/10.1097/MED.0000000000000716

Author

Mathiesen, David S. ; Bagger, Jonatan I. ; Knop, Filip K. / Long-acting amylin analogues for the management of obesity. In: Current Opinion in Endocrinology, Diabetes and Obesity. 2022 ; Vol. 29, No. 2. pp. 183-190.

Bibtex

@article{17ebb4ed9ded43aaad79f496dd6d5d7a,

title = "Long-acting amylin analogues for the management of obesity",

abstract = "PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight. Activity at the calcitonin and amylin receptors in the area postrema seems to - at least partly - be responsible for these effects of amylin. Both preclinical and early-stage clinical studies investigating long-acting amylin receptor analogues demonstrate beneficial effects on body weight in obesity. Cagrilintide, a novel amylin analogue suitable for once-weekly administration, is in phase II clinical development and has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide. SUMMARY: Long-acting amylin analogues have emerged as a possible pharmacotherapy against obesity, but more studies are needed to support the utility and long-term effects of this strategy in relevant populations.",

author = "Mathiesen, {David S.} and Bagger, {Jonatan I.} and Knop, {Filip K.}",

year = "2022",

doi = "10.1097/MED.0000000000000716",

language = "English",

volume = "29",

pages = "183--190",

journal = "Current Opinion in Endocrinology, Diabetes and Obesity",

issn = "1752-296X",

publisher = "Lippincott Williams & Wilkins, Ltd.",

number = "2",

}

RIS

TY - JOUR

T1 - Long-acting amylin analogues for the management of obesity

AU - Mathiesen, David S.

AU - Bagger, Jonatan I.

AU - Knop, Filip K.

PY - 2022

Y1 - 2022

N2 - PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight. Activity at the calcitonin and amylin receptors in the area postrema seems to - at least partly - be responsible for these effects of amylin. Both preclinical and early-stage clinical studies investigating long-acting amylin receptor analogues demonstrate beneficial effects on body weight in obesity. Cagrilintide, a novel amylin analogue suitable for once-weekly administration, is in phase II clinical development and has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide. SUMMARY: Long-acting amylin analogues have emerged as a possible pharmacotherapy against obesity, but more studies are needed to support the utility and long-term effects of this strategy in relevant populations.

AB - PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight. Activity at the calcitonin and amylin receptors in the area postrema seems to - at least partly - be responsible for these effects of amylin. Both preclinical and early-stage clinical studies investigating long-acting amylin receptor analogues demonstrate beneficial effects on body weight in obesity. Cagrilintide, a novel amylin analogue suitable for once-weekly administration, is in phase II clinical development and has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide. SUMMARY: Long-acting amylin analogues have emerged as a possible pharmacotherapy against obesity, but more studies are needed to support the utility and long-term effects of this strategy in relevant populations.

U2 - 10.1097/MED.0000000000000716

DO - 10.1097/MED.0000000000000716

M3 - Journal article

C2 - 35066542

AN - SCOPUS:85125211848

VL - 29

SP - 183

EP - 190

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 2

ER -

ID: 299505700

Department of Clinical Medicine